Why is Alembic Pharma falling/rising?

As of 15-Jul, Alembic Pharmaceuticals Ltd. is currently priced at 1,031.70, reflecting a slight increase of 1.4 (0.14%). The stock has been gaining momentum, having risen 5.82% over the last two days, although it underperformed its sector by 1.11% today. It is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. Despite a year-over-year return of 5.00%, the company's profits have declined by 7%, which may raise concerns among investors. The stock's attractive valuation, evidenced by a low Debt to EBITDA ratio of 0.67 times and strong institutional holdings at 20.37%, suggests that it has the potential for stability, even as its operating profit has seen a negative growth rate of -7.30% over the past five years.
In the broader market context, Alembic Pharmaceuticals has outperformed the benchmark Sensex in the short term, with a 1-week return of +3.31% compared to the Sensex's -1.36%. This indicates that the stock is gaining traction relative to the overall market, despite its long-term challenges. The rising investor participation, as shown by a significant increase in delivery volume, further supports the stock's recent upward movement. However, the negative results reported in March, including a decline in PAT and a high debt-equity ratio, could pose risks that may affect future performance. Overall, while the stock shows short-term strength, underlying issues could impact its long-term growth potential.